CSM Advisors LLC Makes New Investment in Johnson & Johnson $JNJ

CSM Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 126,825 shares of the company’s stock, valued at approximately $19,372,000.

A number of other large investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $218,000. Smart Money Group LLC grew its stake in shares of Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares during the period. Allworth Financial LP increased its holdings in shares of Johnson & Johnson by 1.8% during the 1st quarter. Allworth Financial LP now owns 329,321 shares of the company’s stock valued at $51,022,000 after purchasing an additional 5,958 shares in the last quarter. Finally, Round Rock Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Round Rock Advisors LLC now owns 9,681 shares of the company’s stock valued at $1,605,000 after purchasing an additional 179 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $186.50 on Friday. The stock has a market capitalization of $449.34 billion, a P/E ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. The business has a 50 day simple moving average of $184.25 and a two-hundred day simple moving average of $168.70. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on JNJ shares. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Finally, HSBC increased their target price on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.